Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
03
2019
accepted:
18
04
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
29
2
2020
Statut:
epublish
Résumé
Adoptive transfer of ex vivo expanded tumor infiltrating lymphocytes (TILs) has led to clinical benefit in some patients with melanoma but has not demonstrated convincing efficacy in other solid cancers. Whilst the presence of TILs in many types of cancer is often associated with better clinical prognosis, their function has not been systematically evaluated across cancer types. Responses to immunological checkpoint inhibitors in a wide range of cancers, including those for which adoptive transfer of expanded TILs has not shown clinical benefit, has clearly delineated a number of tumor type associated with tumor-reactive lymphocytes capable of effecting tumor remissions. Neuroblastoma is an aggressive childhood solid cancer in which immunotherapy with GD2-directed antibodies confers a proven survival advantage through incompletely understood mechanisms. We therefore evaluated the feasibility of ex vivo expansion of TILs from freshly resected neuroblastoma tumors and the potential therapeutic utility of TIL expansions. TILs were successfully expanded from both tumor biopsies or resections. Significant numbers of NKT and γδT cells were identified alongside the mixed population of cytotoxic (CD8+) and helper (CD4+) T cells of both effector and central memory phenotypes. Isolated TILs were broadly non-reactive against autologous tumor and neuroblastoma cell lines, so enhancement of neuroblastoma killing was attained by transducing TILs with a second-generation chimeric antigen receptor (CAR) targeting GD2. CAR-TILs demonstrated antigen-specific cytotoxicity against tumor cell lines. This study is the first to show reproducible expansion of TILs from pediatric neuroblastoma, the high proportion of innate-like lymphocytes, and the feasibility to use CAR-TILs therapeutically.
Identifiants
pubmed: 31398192
doi: 10.1371/journal.pone.0216373
pii: PONE-D-19-06821
pmc: PMC6688820
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0216373Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
John Anderson holds company stock in Autolus Ltd and is a paid consultant for TC Biopharm. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Références
Eur Cytokine Netw. 2000 Jun;11(2):217-24
pubmed: 10903800
J Immunother. 2000 Sep-Oct;23(5):536-48
pubmed: 11001547
Immunol Today. 2000 Nov;21(11):573-83
pubmed: 11094262
Gene Ther. 2002 Apr;9(8):527-35
pubmed: 11948378
Blood. 2002 May 1;99(9):3179-87
pubmed: 11964281
Cancer Immunol Immunother. 2003 Jan;52(1):1-9
pubmed: 12536234
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Cancer Immunol Immunother. 2004 Oct;53(10):904-10
pubmed: 15069585
J Exp Med. 2004 May 3;199(9):1213-21
pubmed: 15123743
Cancer Immunol Immunother. 2005 Apr;54(4):400-6
pubmed: 15449039
Oncogene. 2005 Jul 7;24(29):4634-44
pubmed: 15897905
Cancer Res. 2007 Jan 1;67(1):5-8
pubmed: 17210676
Mol Neurobiol. 2006 Dec;34(3):153-61
pubmed: 17308349
J Clin Invest. 2007 Sep;117(9):2702-12
pubmed: 17710228
Nat Med. 2008 Nov;14(11):1264-70
pubmed: 18978797
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Cancer J. 2012 Mar-Apr;18(2):160-75
pubmed: 22453018
Nat Rev Cancer. 2012 Oct;12(10):671-84
pubmed: 22996603
Clin Cancer Res. 2012 Dec 15;18(24):6758-70
pubmed: 23032743
Cancer Immunol Immunother. 2013 Apr;62(4):727-36
pubmed: 23207483
Sci Transl Med. 2013 Mar 20;5(177):177ra38
pubmed: 23515080
Oncoimmunology. 2013 Mar 1;2(3):e23618
pubmed: 23802089
J Immunol. 2013 Sep 1;191(5):2217-25
pubmed: 23904171
Int J Cancer. 2014 Mar 15;134(6):1335-45
pubmed: 24038106
Annu Rev Med. 2014;65:333-47
pubmed: 24274181
Blood. 2014 Aug 21;124(8):1277-87
pubmed: 24970931
Lancet. 2015 Feb 7;385(9967):517-528
pubmed: 25319501
Expert Opin Ther Targets. 2015 Mar;19(3):349-62
pubmed: 25604432
J Carcinog Mutagen. 2014 Dec;5(6):null
pubmed: 25750763
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
Br J Cancer. 2015 Apr 28;112(9):1510-8
pubmed: 25867267
Oncoimmunology. 2014 Dec 23;4(3):e973808
pubmed: 25949890
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Oncoimmunology. 2015 Apr 2;4(9):e1019981
pubmed: 26405592
Oncotarget. 2015 Dec 1;6(38):41339-49
pubmed: 26515587
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Nat Rev Clin Oncol. 2016 May;13(5):273-90
pubmed: 26977780
PLoS One. 2016 Mar 31;11(3):e0152196
pubmed: 27030986
PLoS One. 2016 Apr 06;11(4):e0153053
pubmed: 27050669
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Mol Ther Oncolytics. 2016 Apr 13;3:16006
pubmed: 27162934
Clin Cancer Res. 2017 Jan 15;23(2):466-477
pubmed: 27390347
J Immunother Cancer. 2016 Oct 18;4:61
pubmed: 27777771
Lancet Oncol. 2017 Apr;18(4):500-514
pubmed: 28259608
Mol Ther. 2017 May 3;25(5):1234-1247
pubmed: 28341563
J Hematol Oncol. 2017 Mar 29;10(1):78
pubmed: 28356156
Pediatr Blood Cancer. 2017 Oct;64(10):null
pubmed: 28383769
Cancer Immunol Res. 2017 Jun;5(6):439-445
pubmed: 28473315
Cancer. 2017 Dec 15;123(24):4914-4923
pubmed: 28885700
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Front Oncol. 2018 Mar 02;8:44
pubmed: 29552542
Proc Natl Acad Sci U S A. 1968 Aug;60(4):1231-8
pubmed: 4299942
Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6733-7
pubmed: 7624312
J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66
pubmed: 8028037
Int J Cancer. 1996 Feb 8;65(4):413-21
pubmed: 8621219